The Chicago Consensus on Peritoneal Surface Malignancies: Management of Appendiceal Neoplasms.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
03
07
2019
pubmed:
15
4
2020
medline:
3
2
2021
entrez:
15
4
2020
Statut:
ppublish
Résumé
The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of appendiceal neoplasms specifically related to the management of peritoneal surface malignancies. These guidelines are developed with input from leading experts including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
Identifiants
pubmed: 32285275
doi: 10.1245/s10434-020-08316-w
pii: 10.1245/s10434-020-08316-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1753-1760Investigateurs
Darryl Schuitevoerder
(D)
Alejandro Plana
(A)
Francisco J Izquierdo
(FJ)
Konstantinos I Votanopoulos
(KI)
James C Cusack
(JC)
Lana Bijelic
(L)
Clifford S Cho
(CS)
Alexandra Gangi
(A)
Erin W Gilbert
(EW)
Martin D Goodman
(MD)
Anand Govindarajan
(A)
Vadim Gushchin
(V)
Chukwuemeka Ihemelandu
(C)
Kaitlyn J Kelly
(KJ)
Ryan P Merkow
(RP)
Sam G Pappas
(SG)
Daniel E Abbott
(DE)
Steven A Ahrendt
(SA)
Mazin Al-Kasspooles
(M)
Lindsay Alpert
(L)
Farin Amersi
(F)
Amanda K Arrington
(AK)
Brian Badgwell
(B)
Robert M Barone
(RM)
Joel M Baumgartner
(JM)
Dan G Blazer
(DG)
Richard N Berri
(RN)
Charles Komen Brown
(CK)
Daniel V Catenacci
(DV)
Carlos H F Chan
(CHF)
M Haroon A Choudry
(MHA)
Callisia N Clarke
(CN)
Jordan M Cloyd
(JM)
Abraham H Dachman
(AH)
Jeremiah L Deneve
(JL)
Sean P Dineen
(SP)
Leopoldo J Fernandez
(LJ)
Oliver S Eng
(OS)
James W Fleshman
(JW)
T Clark Gamblin
(T)
Georgios V Georgakis
(GV)
Travis E Grotz
(TE)
Nader Hanna
(N)
Carla Harmath
(C)
John Hart
(J)
Andrea Hayes-Jordan
(A)
Aliya N Husain
(AN)
Kamran Idrees
(K)
Haejin In
(H)
David Jiang
(D)
John M Kane
(JM)
Timothy J Kennedy
(TJ)
Xavier M Keutgen
(XM)
Hedy Lee Kindler
(HL)
Byrne Lee
(B)
Chih-Yi Liao
(CY)
Ugwuji N Maduekwe
(UN)
Grace Z Mak
(GZ)
Lloyd A Mack
(LA)
Melvy Sarah Mathew
(MS)
Marcovalerio Melis
(M)
Nelya Melnitchouk
(N)
Joseph Misdraji
(J)
Harveshp Mogal
(H)
Mecker G Möller
(MG)
Garrett M Nash
(GM)
Aytekin Oto
(A)
Reetesh K Pai
(RK)
Colette R Pameijer
(CR)
Patricio M Polanco
(PM)
Blase N Polite
(BN)
Sanjay S Reddy
(SS)
Richard Royal
(R)
David P Ryan
(DP)
George Salti
(G)
Armando Sardi
(A)
Maheswari Senthil
(M)
Namrata Setia
(N)
Scott K Sherman
(SK)
Lucas Sideris
(L)
Joseph Skitzki
(J)
Jula Veerapong
(J)
Michael G White
(MG)
Joshua H Winer
(JH)
Shu-Yuan Xiao
(SY)
Rhonda K Yantiss
(RK)
Nita Ahuja
(N)
Wilbur Bowne
(W)
Andrew M Lowy
(AM)
H Richard Alexander
(H)
Jesus Esquivel
(J)
Jason M Foster
(JM)
Daniel M Labow
(DM)
Laura A Lambert
(LA)
Edward A Levine
(EA)
Charles Staley
(C)
Paul H Sugarbaker
(PH)
David L Bartlett
(DL)
Kiran Turaga
(K)
Références
Chicago Consensus Working Group. The Chicago Consensus Guidelines for Peritoneal Surface Malignancies: Introduction. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08318-8 .
Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Methodology. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08317-9 .
Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Standards. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08325-9 .
Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Colorectal Metastases. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08315-x .
Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Gastric Metastases. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08320-0 .
Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Peritoneal Mesothelioma. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08324-w .
Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08322-y .
Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Neuroendocrine Tumors. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08321-z .
Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Desmoplastic Small Round Cell Tumor, Breast, and Gastrointestinal Stromal Tumor. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08319-7 .
Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Palliative Care Considerations. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08323-x .
Carr NJ, Bibeau F, Bradley RF, et al. The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei. Histopathology. 2017;71(6):847–858.
doi: 10.1111/his.13324
Carmignani CP, Hampton R, Sugarbaker CE, Chang D, Sugarbaker PH. Utility of CEA and CA 19-9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix. J Surg Oncol. 2004;87(4):162–166.
doi: 10.1002/jso.20107
Koh JL, Liauw W, Chua T, Morris DL. Carbohydrate antigen 19-9 (CA 19-9) is an independent prognostic indicator in pseudomyxoma peritonei post cytoreductive surgery and perioperative intraperitoneal chemotherapy. J Gastrointest Oncol. 2013;4(2):173–181.
pubmed: 23730513
pmcid: 3635178
Wagner PL, Austin F, Sathaiah M, et al. Significance of serum tumor marker levels in peritoneal carcinomatosis of appendiceal origin. Ann Surg Oncol. 2013;20(2):506–514.
doi: 10.1245/s10434-012-2627-5
Chua TC, Chong CH, Liauw W, Zhao J, Morris DL. Inflammatory markers in blood and serum tumor markers predict survival in patients with epithelial appendiceal neoplasms undergoing surgical cytoreduction and intraperitoneal chemotherapy. Ann Surg. 2012;256(2):342–349.
doi: 10.1097/SLA.0b013e3182602ad2
Lohani K, Shetty S, Sharma P, Govindarajan V, Thomas P, Loggie B. Pseudomyxoma peritonei: inflammatory responses in the peritoneal microenvironment. Ann Surg Oncol. 2014;21(5):1441–1447.
doi: 10.1245/s10434-013-3261-6
Olsen IH, Holt N, Langer SW, et al. Goblet cell carcinoids: characteristics of a Danish cohort of 83 patients. PLoS One. 2015;10(2):e0117627.
doi: 10.1371/journal.pone.0117627
Lamarca A, Nonaka D, Lopez Escola C, et al. Appendiceal goblet cell carcinoids: management considerations from a reference peritoneal tumour service centre and ENETS Centre of Excellence. Neuroendocrinology. 2016;103(5):500–517.
doi: 10.1159/000440725
Carr NJ, Cecil TD, Mohamed F, et al., Peritoneal Surface Oncology Group International. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the Peritoneal Surface Oncology Group International (PSOGI) modified Delphi process. Am J Surg Pathol. 2016;40(1):14–26.
Misdraji J, Carr N, Pai R. Tumours of the appendix: mucinous neoplasm. In: WHO Classification of Tumours Editorial Board, editor. Digestive system tumours, vol 1, 5th ed. Lyon: International Agency for Research on Cancer; 2019. p. 144–146.
Misdraji J, Carr N, Pai R. Tumours of the appendix: adenocarcinoma. In: WHO Classification of Tumours Editorial Board, editor. Digestive system tumours, vol 1, 5th ed. Lyon: International Agency for Research on Cancer; 2019. p. 147–148.
Misdraji J, Carr NJ, Pai RK. Tumours of the appendix: goblet cell adenocarcinoma. In: WHO Classification of Tumours Editorial Board, editor. Digestive system tumours, vol 1, 5th ed. Lyon, France: International Agency for Research on Cancer; 2019. p. 149–151.
Tang LH, Shia J, Soslow RA, et al. Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. Am J Surg Pathol. 2008;32(10):1429–1443.
doi: 10.1097/PAS.0b013e31817f1816
Sugarbaker PH, Bijelic L, Chang D, Yoo D. Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. J Surg Oncol. 2010;102(6):576–581.
doi: 10.1002/jso.21679
Asare EA, Compton CC, Hanna NN, et al. The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: analysis of the National Cancer Data Base. Cancer. 2016;122(2):213–221.
doi: 10.1002/cncr.29744
Blackham AU, Swett K, Eng C, et al. Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2014;109(7):740–745.
doi: 10.1002/jso.23547
Shapiro JF, Chase JL, Wolff RA, et al. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer. 2010;116(2):316–322.
doi: 10.1002/cncr.24715
Farquharson AL, Pranesh N, Witham G, et al. A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. Br J Cancer. 2008;99(4):591–596.
doi: 10.1038/sj.bjc.6604522
Lieu CH, Lambert LA, Wolff RA, et al. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol. 2012;23(3):652–658.
doi: 10.1093/annonc/mdr279
Milovanov V, Sardi A, Ledakis P, et al. Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA). Eur J Surg Oncol. 2015;41(5):707–712.
doi: 10.1016/j.ejso.2015.01.005
Turaga KK, Pappas S, Gamblin TC. Right hemicolectomy for mucinous adenocarcinoma of the appendix: just right or too much? Ann Surg Oncol. 2013;20(4):1063–1067.
doi: 10.1245/s10434-012-2783-7
Votanopoulos KI, Shen P, Skardal A, Levine EA. Peritoneal metastases from appendiceal cancer. Surg Oncol Clin N Am. 2018;27(3):551–561.
doi: 10.1016/j.soc.2018.02.007
Moran B, Baratti D, Yan TD, Kusamura S, Deraco M. Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol. 2008;98(4):277–282.
doi: 10.1002/jso.21054
Esquivel J, Averbach A. Laparoscopic cytoreductive surgery and HIPEC in patients with limited pseudomyxoma peritonei of appendiceal origin. Gastroenterol Res Pract. 2012;2012:981245.
doi: 10.1155/2012/981245
Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FA. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2007;245(1):104–109.
doi: 10.1097/01.sla.0000231705.40081.1a
Chua TC, Quinn LE, Zhao J, Morris DL. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases. J Surg Oncol. 2013;108(2):81–88.
doi: 10.1002/jso.23356
Bijelic L, Yan TD, Sugarbaker PH. Treatment failure following complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from colorectal or appendiceal mucinous neoplasms. J Surg Oncol. 2008;98(4):295–299.
doi: 10.1002/jso.21084
Vassos N, Förtsch T, Aladashvili A, Hohenberger W, Croner RS. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis. World J Surg Oncol. 2016;14(1):42.
doi: 10.1186/s12957-016-0804-x
Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6(8):727–731.
doi: 10.1007/s10434-999-0727-7
Stewart JH 4th, Shen P, Russell GB, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol. 2006;13(5):624–634.
doi: 10.1007/s10434-006-9708-2
Yoon W, Alame A, Berri R. Peritoneal Surface Disease Severity Score as a predictor of resectability in the treatment of peritoneal surface malignancies. Am J Surg. 2014;207(3):403–407 (discussion 406–407).
Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol. 2005;2(1):3.
doi: 10.1186/1477-7800-2-3
Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–3743.
doi: 10.1200/JCO.2003.04.187
Levine EA, Votanopoulos KI, Shen P, et al. A multicenter randomized trial to evaluate hematologic toxicities after hyperthermic intraperitoneal chemotherapy with oxaliplatin or mitomycin in patients with appendiceal tumors. J Am Coll Surg. 2018;226(4):434–443.
doi: 10.1016/j.jamcollsurg.2017.12.027